Mean changes in glycemic control parameters between baseline and week 12
| Change from baseline | Comparison to placebo at week 12 | ||||||
| Placebo (n=16) | WBF-010 (n=21) | WBF-011 (n=21) | WBF-010 | WBF-011 | |||
| Mean | P value | Mean | P value | ||||
| Total glucose AUC0-180 (mg/dL/180 min) | 21.2±14.7 | 11.2±8.5 | −14.9±13.8 | −10.0 | 0.5810 (0.1270*) | −36.1 | 0.0500 (0.0143*) |
| A1c (%) | 0.4±0.2 | 0.2±0.2 | −0.2±0.2 | −0.2 | 0.4684 | −0.6 | 0.0540 |
| Fasting plasma glucose (mg/dL) | 2.8±10.8 | 14.8±7.5 | −3.0±11.2 | 12.0 | 0.4099 | −5.8 | 0.6890 |
| Incremental glucose AUC0-180 (mg/dL/180 min) | 16.9±7.4 | −3.6±6.1 | −11.7±7.2 | −20.4 | 0.0482 | −28.6 | 0.0066 |
| Total insulin AUC0-180 (µIU/mL/180 min) | −2.2±4.6 | −2.9±2.9 | 4.4±4.5 | −0.7 | 0.9070 | 6.6 | 0.2718 |
| Incremental insulin AUC0-180 (µIU/mL/180 min) | −3.3±4.4 | −2.0±2.7 | 1.5±4.0 | 1.3 | 0.8197 | 4.8 | 0.3825 |
| HOMA-IR | 0.8±0.7 | −0.1±0.7 | 0.8±0.6 | −0.9 | 0.4088 | 0.0 | 0.9782 |
See model estimates in online supplementary figure S6 and Methods section for further details.
*P values from the stepwise-selected model defined in the Statistical Analysis Plan (online supplementary text S2).
AUC, area under the curve; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance.